Robert H. Vonderheide, MD, DPhil, Discusses Genomic Correlates of Response to Chemoimmunotherapy in PDAC
Biosignatures data from the PRINCE trial show sophisticated precision approaches may be necessary to optimize chemoimmunotherapy use in pancreatic ductal adenocarcinoma.